Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review (vol 11, pg 1, 2019)

被引：0
|
作者：
Chiorean, Elena Gabriela
Cheung, Winson Y.
Giordano, Guido
Kim, George
Al-Batran, Salah-Eddin
机构：
来源：
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2019年 / 11卷
关键词：
D O I：
10.1177/1758835919871363
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Reinitiating nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer
    Borazanci, Erkut
    Schroeder, Katy
    Jameson, Gayle S.
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [42] Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer
    Blomstrand, Hakon
    Scheibling, Ursula
    Bratthall, Charlotte
    Green, Henrik
    Elander, Nils O.
    BMC CANCER, 2019, 19 (1)
  • [43] nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: Real life
    Cidon, E. Una
    Alonso, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S109 - S109
  • [44] Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study
    Li, Haorui
    Guo, Yu
    Sun, Xugang
    Lu, Yang
    Chang, Shaofei
    Wang, Xiuchao
    Gao, Song
    Gao, Chuntao
    Zhao, Tiansuo
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [45] Real-world cost-effectiveness of first-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX in patients with advanced pancreatic cancer: A population-based retrospective cohort study in Ontario, Canada
    Arciero, Vanessa
    Luo, Jin
    Parmar, Ambika
    Dai, Wei Fang
    Beca, Jaclyn M.
    Raphael, Michael J.
    Isaranuwatchai, Wanrudee
    Habbous, Steven
    Tadrous, Mina
    Earle, Craig
    Biagi, Jim
    Mittmann, Nicole
    Arias, Jessica
    Gavura, Scott
    Chan, Kelvin K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [46] Comparative effectiveness of FOLFIRINOX (FOL) versus gemcitabine and nab-paclitaxel (GNP) for the first-line treatment of metastatic pancreatic cancer
    Cheng, Wei-Han
    Sadeghi, Sarmad
    Lenz, Heinz-Josef
    Hay, Joel W.
    Barzi, Afsaneh
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [47] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicenter, randomized, phase II study
    Jin, Min
    Liu, Hong-Li
    Xue, Jun
    Ma, Hong
    Liu, Jun-Li
    Lin, Zhen-Yu
    Wang, Jing
    Bao, Le-Qun
    Luo, Zhi-Guo
    Yu, Xiong-Jie
    Li, Shuang
    Hu, Jian-Li
    Zhang, Tao
    ONCOLOGIST, 2024, 29 (10): : e1406 - e1418
  • [48] Maintenance treatment with gemcitabine after gemcitabine plus Nab-paclitaxel in advanced pancreatic cancer
    Kodama, Tomoko
    Nakazawa, Junichi
    Kawahira, Masahiro
    Ymasuji, Akihiro
    Iwashita, Yuji
    Hori, Takeshi
    Kawahira, Machiko
    Arima, Shiho
    Tubouchi, Hirohito
    Ido, Akio
    ANNALS OF ONCOLOGY, 2022, 33 : S484 - S484
  • [49] Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study
    Sonia Zaibet
    Vincent Hautefeuille
    Edouard Auclin
    Astrid Lièvre
    David Tougeron
    Mathieu Sarabi
    Marine Gilabert
    Julie Wasselin
    Julien Edeline
    Pascal Artru
    Dominique Bechade
    Clémence Morin
    Agnes Ducoulombier
    Julien Taieb
    Simon Pernot
    British Journal of Cancer, 2022, 126 : 1394 - 1400
  • [50] Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial
    Kunzmann, Volker
    Siveke, Jens T.
    Alguel, Hana
    Goekkurt, Eray
    Siegler, Gabriele
    Martens, Uwe
    Waldschmidt, Dirk
    Pelzer, Uwe
    Fuchs, Martin
    Kullmann, Frank
    Boeck, Stefan
    Ettrich, Thomas J.
    Held, Swantje
    Keller, Ralph
    Klein, Ingo
    Germer, Christoph-Thomas
    Stein, Hubert
    Friess, Helmut
    Bahra, Marcus
    Jakobs, Ralf
    Hartlapp, Ingo
    Heinemann, Volker
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (02): : 128 - 138
12345